Abstract: The present invention relates to a process for preparing sordidin, comprising a step of preparing 4-(2-ethyl-1,3-dioxolan-2-yl)pentan-2-one by means of a reaction in which 2-ethyl-2-(pent-4-en-2-yl)-1,3-dioxolane is oxidized in the presence of a catalyst chosen from the group comprising organometallic complexes of transition metals.

Abstract: The present invention provides compositions useful in reducing or preventing pain in a subject in need thereof. In certain embodiments, the compositions comprise a halogenated volatile compound. The present invention further includes a method of reducing or preventing pain in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of at least one composition of the invention. Dosing regimens contemplated within the invention include one-time administration, continuous administration or periodic administration.

Abstract: A process for preparation of (2S,5R)-7-oxo-6-sulphooxy-2-[((3R)-piperidine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza-bicyclo[3.2.1]octane of Formula (I) is disclosed which is comprising reacting a compound of Formula (II) with a compound of Formula (III) to obtain a compound of Formula (IV). Crystalline compounds of Formula (I) are claimed.

Abstract: In one embodiment, the present application discloses mixtures comprising (a) water in an amount of at least 1% wt/wt of the mixture; (b) a transition metal catalyst; and (c) one or more solubilizing agents; and methods for using such mixtures for performing transition metal mediated bond formation reactions.

Abstract: Equatorial 2,3-fluorinated glycosides compounds of formula (I) useful for the treatment or prophylaxis of viral infection, particularly viral influenza, the methods for their preparation, and their pharmaceutical compositions. The therapeutic effect is achieved via inhibition of viral neuraminidases.

Abstract: Described are stability-enhancing formulations of drugs that are sensitive to moisture. The formulations comprise co-granulates containing a moisture-sensitive drug and an excipient selected from fructose, xylitol, maltitol, and mixtures thereof. Also described are methods of producing a pharmaceutical tablet. The method comprises forming a blend of a moisture-sensitive drug and a first excipient selected from fructose, xylitol, maltitol, and mixtures thereof; spraying the blend with water to produce granules; drying and milling the granules; mixing a second excipient with the granules; and compressing into tablets.

Abstract: The present invention provides an efficient method of synthesizing and purifying dianhydrohexitols such as dianhydrogalactitol. In general, as applied to dianhydrogalactitol, the method comprises: (1) reacting dulcitol with a concentrated solution of hydrobromic acid at a temperature of about 80° C. to produce dibromogalactitol; (2) reacting the dibromogalactitol with potassium carbonate in t-butanol to produce dianhydrogalactitol; and (3) purifying the dianhydrogalactitol using a slurry of ethyl ether to produce purified dianhydrogalactitol. Another method produces dianhydrogalactitol from dulcitol; this method comprises: (1) reacting dulcitol with a reactant to convert the 1,6-hydroxy groups of dulcitol to an effective leaving group to generate an intermediate; and (2) reacting the intermediate with an inorganic weak base to produce dianhydrogalactitol through an intramolecular SN2 reaction. Other methods for the synthesis of dianhydrogalactitol from dulcitol are described.

Abstract: A method for mitigating erectile dysfunction as an adverse side effect of radiation therapy for prostate cancer, comprising administration of a therapeutic dosage of genistein to a patient diagnosed with prostate cancer throughout only a primary administration period that commences a defined period of up to two weeks prior to commencement of radiation therapy for prostate cancer and extends beyond conclusion of the radiation therapy.

Abstract: A process to produce furandicarboxylic acid (FDCA). The process includes the steps of reacting a C6 sugar-containing reactant in a reaction solution comprising a first organic solvent selected from the group consisting of beta-, gamma-, and delta-lactones, hydrofurans, hydropyrans, and combinations thereof, in the presence of an acid catalyst for a time and under conditions wherein at least a portion of the C6 sugar present in the reactant is converted to 5-(hydroxymethyl)furfural (HMF); oxidizing the HMF into FDCA with or without separating the HMF from the reaction solution; and extracting the FDCA by adding an aprotic organic solvent having a dipole moment of about 1.0 D or less to the reaction solution.

Abstract: The present disclosure generally relates to a silica-titanium catalyst prepared by first reacting a solid support with a metal alkoxide and then depositing titanium onto the solid support for the epoxidation of alkenes and aralkenes and a method of preparing the catalyst thereof. In some embodiments, the present disclosure relates to methods of using the catalyst described herein for the production of epoxides.

Abstract: The present invention relates to the a process for total synthesis of flavonoid compounds of general formula I and isomers thereof wherein R1 and R2 is OH; R3?H or The present invention particularly relates to the process for preparation and separation of (2S,3S)-taxifolin-6-C-?-D-glucopyranoside (ulmoside A), (2R,3R)-taxifolin-6-C-?-D-glucopyranoside and taxifolin.

Abstract: Described herein are coating compositions for consumer and/or medical products. The coating compositions can be used to confer desirable properties to the consumer and/or medical products.

Abstract: A process for preparation of compound of Formula (I) is disclosed. The application is also directed to polymorphic forms of the compound of formula (I).

Abstract: The present invention relates compounds according to Formula (I) wherein R1 and R2 are independently H or an optionally substituted group selected from an alkyl, a heteroalkyl, an aryl, a heteroaryl, an arylalkyl, and a heteroarylalkyl, and R3 and R4 taken together form a carbonyl (?O); or wherein R1 and R2 are independently H or an optionally substituted group selected from an alkyl, a heteroalkyl, an aryl, a heteroaryl, an arylalkyl, and a heteroarylalkyl, R3 is H and R4 is H or —OR5, wherein R5 is H or an optionally substituted group selected from an alkyl, a heteroalkyl, an aryl, a heteroaryl, an arylalkyl, and a heteroarylalkyl; or pharmaceutically acceptable salts or esters thereof, for use in the treatment of kidney disease, in particular in the treatment of acute kidney injury. The present invention also relates to methods of treatment of the same and methods of kidney transplant surgery and coronary artery bypass graft surgery using the compounds of Formula (I).

Abstract: The present invention provides methods of inhibiting abnormal growth of cells, with the methods comprising contacting the cells with at least one of the sensitizing compounds disclosed herein in an amount sufficient to inhibit cell growth. The present invention also provides methods of treating and/or reducing the likelihood of being diagnosed with breast cancer, with the methods comprising administering to a subject in need of treatment thereof at least one of the sensitizing compounds disclosed herein.

Abstract: The present invention is concerned with a method for producing tetrahydrofuran including carrying out a dehydration cyclization reaction of 1,4-butanediol in the presence of an acid catalyst having a pKa value of not more than 4 within a reactor, wherein a raw material liquid containing 1,4-butanediol to be provided for the reaction contains from 0.01 to 0.35% by weight of 2-(4-hydroxybutoxy)-tetrahydrofuran and 1 ppm by weight or more and not more than 1,000 ppm by weight of at least one of an amine and an amide in terms of a concentration as converted into a nitrogen atom.

Abstract: The present invention relates to the use of canthaxanthin and at least one vitamin D metabolite, preferably 25-hydroxy vitamin D3 (25-OH D3), for improving internal egg quality. Interior egg quality, usually expressed in Haugh Units, is prolonged by feeding the laying poultry a diet containing canthaxanthin and 25-hydroxy vitamin D3.

Abstract: The present disclosure discloses an ?-alumina carrier, comprising the elements of lanthanum and silicon both dispersed in the interior and on the surface of the carrier. The mass ratio of the element of lanthanum to the element of silicon is in the range from 0.1:1 to 20:1. The inventors of the present disclosure have made extensive researches into the field of the silver catalyst and alumina carrier thereof, and added the elements of lanthanum and silicon (i.e., bulk phase addition) in preparing the alumina carrier used in the silver catalyst. The carrier thus obtained contains the elements of silicon and lanthanum both in the interior and on the surface thereof, and has improved specific surface area and strength. The silver catalyst prepared with the carrier can react in a low reaction temperature (has a high reaction activity) and has a high selectivity in producing ethylene oxide through oxidation of ethylene.

Abstract: The invention relates to a family of differently substituted benzothiazoles having inhibitory activity against casein kinase 1 (CK-1) enzyme, as a result of which they are suitable for use in the treatment or prevention of diseases caused by this enzyme, particularly diseases associated with circadian rhythm and inflammatory, autoimmune, psychiatric, neurodegenerative, neurological or ophthalmic diseases, as well as for inducing cell regeneration

Abstract: A process for manufacturing epoxy monomers and/or epoxides in high yields and useful quality and chemical stability by dehydrochlorination of the corresponding chlorohydrins with an alkaline agent, producing the corresponding side product dry salt in a high purity, characterized in that the process comprises the following steps: a. Reaction of the chlorohydrins with the alkaline agent to form corresponding epoxides and the corresponding precipitated chloride salt; b. Dehydration, and optionally completing the reaction, of the reaction mixture of step (a), by use of an azeotropic agent, added to step (b) or generated in situ in step (a), resulting in the producing of a dehydrated reaction mixture; c. Separating the resulting chloride salt by filtration from the dehydrated reaction mixture (b) and d. Isolating the epoxide from the filtered liquid fraction.